Stories
Hospital Stocks Plunge as Supreme Court Scrutinizes Drug Pricing Caps
C
CNBC TV18•12-10-2026, 15:24
Hospital Stocks Plunge as Supreme Court Scrutinizes Drug Pricing Caps
- •Shares of major hospital chains including Apollo Hospitals, Fortis Healthcare, Max Healthcare, and Aster DM saw significant sell-offs on Monday following Supreme Court hearings on drug price caps.
- •The Supreme Court questioned why the government cannot control the entire drug market and pointed out that medicines are often sold at tenfold their manufacturing costs.
- •The government defended its position stating the need for a balance between pricing and availability while noting India already has some of the lowest global drug prices.
- •The apex court previously described steep hospital markups on cancer medicines as a carnage and suggested a uniform 16 percent margin on all drugs.
- •The next court hearing is scheduled for Tuesday, October 27, keeping investor sentiment cautious across healthcare stocks.
Key Questions Answered
Shares of hospital operators such as Apollo Hospitals, Fortis Healthcare, Max Healthcare, and Aster DM dropped following the conclusion of a Supreme Court hearing regarding drug price caps on Monday. The selloff was driven by ongoing regulatory concerns surrounding medicine pricing in private healthcare.
The government stated in the Supreme Court that it is not looking to control the entire drug market because India already has the lowest global prices. However, the apex court questioned why the entire market cannot be regulated, pointing out that manufacturers often sell drugs at ten times their MRP after accounting for R&D costs.
The next Supreme Court hearing regarding the drug price caps is scheduled to take place on Tuesday, October 27.
